MoonLake Immunotherapeutics
Generated by Meeveem AI
"Unlocking Nanobody® technology to revolutionize outcomes for patients with inflammatory diseases"
Zug
•51 - 250 Employees
•Biotechnology
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody® designed to treat serious inflammatory diseases. Sonelokimab targets IL-17A and IL-17F, the key drivers behind conditions like hidradenitis suppurativa, psoriatic arthritis, psoriasis and ankylosing spondylitis, long term conditions that severely impact patients' lives. The company moves the clinical paradigm beyond conventional antibodies by penetrating difficult to reach inflamed tissues and joints. MoonLake combines revolutionary Nanobody® technology with deep immunology expertise to elevate treatment horizons and address critical unmet patient needs.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
130
Team Members
2021
Founded
Public
Funding
Hybrid
Work Environment
Our Vision
A world where patients with inflammatory diseases achieve transformative outcomes through breakthrough therapies that reach where traditional treatments cannot.
Our Mission
MoonLake exists to revolutionize outcomes for patients living with serious inflammatory diseases by unlocking the full potential of Sonelokimab, our novel investigational Nanobody® therapy.